Evidence map›Paper›PMID 42435620›Full record

ArticleVaccine2026

Vaccinia virus and Monkeypox virus neutralizing and antigen-binding antibodies following subcutaneous and reduced intradermal doses of an MVA vaccine.

Bernard Moss, Catherine A Cotter, Jeffrey L Americo, Maxinne A Ignacio, Jocelyn E Bassler, Sharon E Frey, John H Beigel

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Bernard MossLaboratory of Viral Diseases, NIAID, NIH, Bethesda, MD, USA. Electronic address: bmoss@niaid.nih.gov.
Catherine A CotterLaboratory of Viral Diseases, NIAID, NIH, Bethesda, MD, USA.
Jeffrey L AmericoLaboratory of Viral Diseases, NIAID, NIH, Bethesda, MD, USA.
Maxinne A IgnacioLaboratory of Viral Diseases, NIAID, NIH, Bethesda, MD, USA.
Jocelyn E BasslerApplied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
Sharon E FreyCenter for Vaccine Development, Division of Infectious Diseases, Saint Louis University Medical School, St. Louis, MO, USA.
John H BeigelDivision of Microbiology and Infectious Diseases, NIAID, NIH, Bethesda, MD, USA.

Funding

Poxvirus pathogenesis and immunityZ01AI000979 · NIAID · NIAID EXTRAMURAL ACTIVITIES · PI MOSS, BERNARD · 2006 to 2008
$2.0M
Intramural NIH HHS Z01 AI000979
6 · The paper itself

Abstract

To expand the supply of the modified vaccinia Ankara (MVA) smallpox/mpox vaccine, fractional doses administered intradermally (ID) have been considered as alternatives to the standard dose given subcutaneously (SC). In a recent clinical trial, participants received the standard 10

Indexed as

Antibodies, NeutralizingAntibodies, ViralAntigens, ViralMonkeypox virusSmallpox VaccineVaccinia virusFemaleHumansInjections, IntradermalInjections, SubcutaneousMpox, MonkeypoxNeutralization TestsAntibodies, NeutralizingAntibodies, ViralAntigens, ViralSmallpox VaccineModified vaccinia virus AnkaraMonkeypox virus neutralizationMpox vaccineNeutralizing antibodies

Identifiers

PMID42435620
PMCPMC13408762

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.